DKK1 and plasma cell myeloma: Additionally, DKK1 orchestrates the accrual and function of MDSCs in malignancies, is ubiquitously acknowledged as a potent tumor-affiliated antigen in multiple myeloma, and has been anointed as an innovative immunotherapy target for myeloma [27–29].